Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.46 |
| ▸ | ADK | P55263 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 2/20 | 0.45 |
| ▸ | SKP1 | P63208 | 2/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265889 | 0.90 | MAP4K4 (0.60) | MAP4K4GPR119ADKCKS1BSKP1 | |
| SCHEMBL29612182 | 0.90 | MAP4K4 (0.60) | MAP4K4GPR119ADKCKS1BSKP1 | |
| SCHEMBL15827745 | 0.85 | PPARG (0.48) | MAP4K4GPR119CKS1BSKP1SKP2 | |
| SCHEMBL2395123 | 0.85 | CKS1B (0.59) | MAP4K4GPR119ADKCKS1BSKP1 | |
| SCHEMBL13100992 | 0.84 | AKR1C3 (0.51) | MAP4K4GPR119ADKCKS1BSKP1 | |
| SCHEMBL23783219 | 0.82 | GPR119 (0.68) | MAP4K4GPR119DDB1CRBN | |
| SCHEMBL31329736 | 0.82 | GPR119 (0.68) | MAP4K4GPR119DDB1CRBN | |
| SCHEMBL30010609 | 0.82 | RET (0.51) | MAP4K4GPR119ADKCKS1BSKP1 | |
| SCHEMBL15986821 | 0.81 | HDAC1 (0.66) | MAP4K4GPR119HDAC1 | |
| SCHEMBL18822849 | 0.81 | HDAC1 (0.66) | MAP4K4GPR119HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785625-B2 | Compound having heterocyclic ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8530646-B2 | Oxazolidinone derivative having 7-membered hetero ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530646-B2 | Oxazolidinone derivative having 7-membered hetero ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20120208997-A1 | NOVEL COMPOUND HAVING HETEROCYCLIC RING | SUZUKI HIDEYUKI (JP) | 2012-08-16 | — | — | US | disclosed |
| US-20120208997-A1 | NOVEL COMPOUND HAVING HETEROCYCLIC RING | SUZUKI HIDEYUKI (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8148362-B2 | Compound having heterocyclic ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8148362-B2 | Compound having heterocyclic ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. | 2010-10-07 | — | — | US | disclosed |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. | 2010-10-07 | — | — | US | disclosed |
| EP-2208729-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | Research Foundation Itsuu Laboratory (JP) | 2010-07-21 | — | — | EP | disclosed |
| EP-2181994-A1 | Antimicrobial compounds | Research Foundation Itsuu Laboratory (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20090299059-A1 | Novel Compound Having Heterocyclic Ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2009-12-03 | — | — | US | disclosed |
| US-20090299059-A1 | Novel Compound Having Heterocyclic Ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299059-A1 | Novel Compound Having Heterocyclic Ring | NR0B2, NR2C2, NR0B1 | MAP4K4 4459/4885GPR119 682/4885ADK 4086/4885 |
| US-20120208997-A1 | NOVEL COMPOUND HAVING HETEROCYCLIC RING | OXA1L, MRPL21, TOP1 | MAP4K4 2924/4885GPR119 2177/4885ADK 3268/4885 |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | NR0B2, NR0B1, NR2C2 | MAP4K4 4561/4885GPR119 1388/4885ADK 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.